{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:19:53Z","timestamp":1789885193431,"version":"4.0.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Hypertension remains a major chronic disease morbidity across the world, even in the twenty-first century, affecting \u224840% of the global population, adversely impacting the healthcare budgets in managing the high incidence of cardiovascular disease (CVD) complications and mortality because of elevated blood pressure (BP). However, evaluation and management of endocrine hypertension are not optimal in clinical practice. With three unique clinical case scenarios, we update the evidence base for diagnostic evaluation and management of endocrine hypertension in this review to inform appropriate day-to-day clinical practice decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Although most individuals with high BP suffer from essential hypertension (\u224885%), some patients may have a clear underlying etiology (termed secondary hypertension), and a significant proportion of these patients have endocrine hypertension (\u224810%) consequent to hormone excess from dysfunction of one or more endocrine glands. Even if a relatively common disease in the general population, the correct diagnosis and appropriate treatment of endocrine hypertension is often delayed because of poor awareness among clinicians, including primary care providers and physicians in the secondary care settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>An accurate and timely diagnosis of endocrine hypertension is crucial to potentially cure or at least properly manage these patients because the consequences of delays in diagnosis can be catastrophic, with markedly higher end-organ complications such as CVD, chronic kidney disease, and even premature mortality among sufferers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11906-025-01323-w","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T04:27:40Z","timestamp":1737001660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Approach to Endocrine Hypertension: A Case-Based Discussion"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2042-4359","authenticated-orcid":false,"given":"Sanja","family":"Borozan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5681-6522","authenticated-orcid":false,"given":"A. B. M.","family":"Kamrul-Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahana","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-5255","authenticated-orcid":false,"given":"Joseph M.","family":"Pappachan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"1323_CR1","doi-asserted-by":"publisher","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet. 2019;394(10199):639\u2013651. https:\/\/doi.org\/10.1016\/S0140-6736(19)31145-6.","DOI":"10.1016\/S0140-6736(19)31145-6"},{"issue":"2","key":"1323_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.17925\/EE.2023.19.2.11","volume":"19","author":"CJ Fernandez","year":"2023","unstructured":"Fernandez CJ, Nagendra L, Alkhalifah M, Pappachan JM. Endocrine hypertension: The urgent need for greater global awareness. touchREV Endocrinol. 2023;19(2):31\u201341.","journal-title":"touchREV Endocrinol"},{"issue":"14","key":"1323_CR3","doi-asserted-by":"publisher","first-page":"e025952","DOI":"10.1161\/JAHA.122.025952","volume":"11","author":"AF Turcu","year":"2022","unstructured":"Turcu AF, Nhan W, Grigoryan S, Zhang L, Urban C, Liu H, Holevinski L, Zhao L. Primary aldosteronism screening rates differ with sex, race, and comorbidities. J Am Heart Assoc. 2022;11(14):e025952. https:\/\/doi.org\/10.1161\/JAHA.122.025952.","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"1323_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11906-020-01108-3","volume":"22","author":"T de Silva","year":"2020","unstructured":"de Silva T, Cosentino G, Ganji S, Riera-Gonzalez A, Hsia DS. Endocrine causes of hypertension. Curr Hypertens Rep. 2020;22(11):97. https:\/\/doi.org\/10.1007\/s11906-020-01108-3.","journal-title":"Curr Hypertens Rep"},{"issue":"5","key":"1323_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/clinchem\/hvae022","volume":"70","author":"L Courcelles","year":"2024","unstructured":"Courcelles L, Stoenoiu M, Haufroid V, Lopez-Sublet M, Boland L, Wauthier L, Beauloye C, Maiter D, Januszewicz A, Kreutz R, Persu A, Gruson D. Laboratory testing for endocrine hypertension: Current and future perspectives. Clin Chem. 2024;70(5):709\u201326. https:\/\/doi.org\/10.1093\/clinchem\/hvae022.","journal-title":"Clin Chem"},{"issue":"12","key":"1323_CR6","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1038\/s41440-023-01461-1","volume":"46","author":"JB de Freminville","year":"2023","unstructured":"de Freminville JB, Amar L, Azizi M, Mallart-Riancho J. Endocrine causes of hypertension: literature review and practical approach. Hypertens Res. 2023;46(12):2679\u201392. https:\/\/doi.org\/10.1038\/s41440-023-01461-1.","journal-title":"Hypertens Res"},{"key":"1323_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/5584_2016_26","volume":"956","author":"JM Pappachan","year":"2017","unstructured":"Pappachan JM, Buch HN. Endocrine hypertension: A practical approach. Adv Exp Med Biol. 2017;956:215\u201337. https:\/\/doi.org\/10.1007\/5584_2016_26.","journal-title":"Adv Exp Med Biol"},{"key":"1323_CR8","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"1323_CR9","doi-asserted-by":"publisher","first-page":"e079108","DOI":"10.1136\/bmj-2023-079108","volume":"385","author":"EL Schiffrin","year":"2024","unstructured":"Schiffrin EL, Fisher NDL. Diagnosis and management of resistant hypertension. BMJ. 2024;385:e079108. https:\/\/doi.org\/10.1136\/bmj-2023-079108.","journal-title":"BMJ"},{"key":"1323_CR10","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1097\/01.hjh.0000748668.13052.17","volume":"39","author":"T Kvapil","year":"2021","unstructured":"Kvapil T, Vaclavik J, Benesova K, Jarkovsky J, Kocianova E, Kamasova M, et al. Prevalence of secondary hypertension in patients with resistant arterial hypertension. J Hypertens. 2021;39:e357. https:\/\/doi.org\/10.1097\/01.hjh.0000748668.13052.17.","journal-title":"J Hypertens"},{"issue":"1","key":"1323_CR11","first-page":"3","volume":"45","author":"JW Conn","year":"1955","unstructured":"Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45(1):3\u201317.","journal-title":"J Lab Clin Med"},{"issue":"12","key":"1323_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/ajh\/hpac079","volume":"35","author":"A Vaidya","year":"2022","unstructured":"Vaidya A, Hundemer GL, Nanba K, Parksook WW, Brown JM. Primary aldosteronism: State-of-the-art review. Am J Hypertens. 2022;35(12):967\u201388. https:\/\/doi.org\/10.1093\/ajh\/hpac079.","journal-title":"Am J Hypertens"},{"issue":"1","key":"1323_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12022-022-09710-8","volume":"33","author":"O Mete","year":"2022","unstructured":"Mete O, Erickson LA, Juhlin CC, de Krijger RR, Sasano H, Volante M, Papotti MG. Overview of the 2022 WHO classification of adrenal cortical tumors. Endocr Pathol. 2022;33(1):155\u201396. https:\/\/doi.org\/10.1007\/s12022-022-09710-8.","journal-title":"Endocr Pathol"},{"issue":"4","key":"1323_CR14","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvae041","volume":"190","author":"P Mulatero","year":"2024","unstructured":"Mulatero P, Scholl UI, Fardella CE, Charmandari E, Januszewicz A, Reincke M, Gomez-Sanchez CE, Stowasser M, Dekkers OM. Familial hyperaldosteronism: an European reference network on rare endocrine conditions clinical practice guideline. Eur J Endocrinol. 2024;190(4):G1\u201314. https:\/\/doi.org\/10.1093\/ejendo\/lvae041.","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"1323_CR15","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/HJH.0000000000002510","volume":"38","author":"P Mulatero","year":"2020","unstructured":"Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro MC, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension. J Hypertens. 2020;38(10):1919\u201328. https:\/\/doi.org\/10.1097\/HJH.0000000000002510.","journal-title":"J Hypertens"},{"key":"1323_CR16","doi-asserted-by":"crossref","unstructured":"Stowasser M, Jansen P, Wolley M. Systematic approach to the diagnosis and management of endocrine hypertension. In: Pappachan JM, Fernandez CJ, editors. Endocrine Hypertension: From Basic Science to Clinical Practice. Eastbourne, UK: Elsevier; 2022. p. 331\u201368.","DOI":"10.1016\/B978-0-323-96120-2.00009-1"},{"key":"1323_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrneph.2010.30","volume":"6","author":"M Briet","year":"2010","unstructured":"Briet M, Schiffrin E. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010;6:261\u201373.","journal-title":"Nat Rev Nephrol"},{"key":"1323_CR18","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.3390\/ijms23094803","volume":"23","author":"F Bioletto","year":"2022","unstructured":"Bioletto F, Bollati M, Lopez C, Arata S, Procopio M, Ponzetto F, et al. Primary aldosteronism and resistant hypertension: A pathophysiological insight. Int J Mol Sci. 2022;23:4803. https:\/\/doi.org\/10.3390\/ijms23094803.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1323_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41574-022-00730-2","volume":"18","author":"AF Turcu","year":"2022","unstructured":"Turcu AF, Yang J, Vaidya A. Primary aldosteronism - a multidimensional syndrome. Nat Rev Endocrinol. 2022;18(11):665\u201382. https:\/\/doi.org\/10.1038\/s41574-022-00730-2.","journal-title":"Nat Rev Endocrinol"},{"issue":"22","key":"1323_CR20","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1016\/j.jacc.2019.09.057","volume":"74","author":"G Rossi","year":"2019","unstructured":"Rossi G. Primary aldosteronism: JACC state-of-the-art review. JACC. 2019;74(22):2799\u2013811. https:\/\/doi.org\/10.1016\/j.jacc.2019.09.057.","journal-title":"JACC"},{"key":"1323_CR21","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1210\/jc.2016-1472","volume":"101","author":"SC Kayser","year":"2016","unstructured":"Kayser SC, Dekkers T, Groenewoud HJ, van der Wilt GJ, Carel Bakx J, van der Wel MC, et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab. 2016;101:2826\u201335.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1323_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1055\/a-1134-4980","volume":"52","author":"S Gruber","year":"2020","unstructured":"Gruber S, Beuschlein F. Hypokalemia and the prevalence of primary aldosteronism. Horm Metab Res. 2020;52(6):347\u201356. https:\/\/doi.org\/10.1055\/a-1134-4980.","journal-title":"Horm Metab Res"},{"key":"1323_CR23","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889\u2013916.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"1323_CR24","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1210\/clinem\/dgab348","volume":"106","author":"A Hung","year":"2021","unstructured":"Hung A, Ahmed S, Gupta A, Davis A, Kline GA, Leung AA, Ruzicka M, Hiremath S, Hundemer GL. Performance of the aldosterone to renin ratio as a screening test for primary aldosteronism. J Clin Endocrinol Metab. 2021;106(8):2423\u201335. https:\/\/doi.org\/10.1210\/clinem\/dgab348.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1323_CR25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/ajh\/hpab189","volume":"35","author":"WW Parksook","year":"2022","unstructured":"Parksook WW, Yozamp N, Hundemer GL, Moussa M, Underhill J, Fudim T, Sacks B, Vaidya A. Morphologically normal-appearing adrenal glands as a prevalent source of aldosterone production in primary aldosteronism. Am J Hypertens. 2022;35(6):561\u201371. https:\/\/doi.org\/10.1093\/ajh\/hpab189.","journal-title":"Am J Hypertens"},{"issue":"1","key":"1323_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1161\/HYPERTENSIONAHA.121.18284","volume":"79","author":"GP Rossi","year":"2022","unstructured":"Rossi GP, Crim\u00ec F, Rossitto G, Amar L, Azizi M, Riester A, et al. Feasibility of imaging-guided adrenalectomy in young patients with primary aldosteronism. Hypertension. 2022;79(1):187\u201395. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.121.18284.","journal-title":"Hypertension"},{"issue":"1","key":"1323_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3978\/j.issn.2227-684X.2015.01.05","volume":"4","author":"M Iacobone","year":"2015","unstructured":"Iacobone M, Citton M, Viel G, Rossi GP, Nitti D. Approach to the surgical management of primary aldosteronism. Gland Surg. 2015;4(1):69\u201381. https:\/\/doi.org\/10.3978\/j.issn.2227-684X.2015.01.05.","journal-title":"Gland Surg"},{"issue":"8","key":"1323_CR28","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","volume":"38","author":"JWM Lenders","year":"2020","unstructured":"Lenders JWM, Kerstens MN, Amar L, Prejbisz A, Robledo M, Taieb D, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension. J Hypertens. 2020;38(8):1443\u201356. https:\/\/doi.org\/10.1097\/HJH.0000000000002438.","journal-title":"J Hypertens"},{"issue":"2","key":"1323_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1210\/endrev\/bnab019","volume":"43","author":"S N\u00f6lting","year":"2022","unstructured":"N\u00f6lting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M, Eisenhofer G, Grossman A, Pacak K. Personalized management of pheochromocytoma and paraganglioma. Endocr Rev. 2022;43(2):199\u2013239. https:\/\/doi.org\/10.1210\/endrev\/bnab019. (Erratum in: Endocr Rev. 2022 Mar 9;43(2):440. 10.1210\/endrev\/bnab044. Erratum in: Endocr Rev. 2022 Mar 9;43(2):437-439. 10.1210\/endrev\/bnab045).","journal-title":"Endocr Rev"},{"issue":"6","key":"1323_CR30","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1007\/s00268-012-1488-1","volume":"36","author":"J Kirkby-Bott","year":"2012","unstructured":"Kirkby-Bott J, Brunaud L, Mathonet M, Hamoir E, Kraimps JL, Tr\u00e9sallet C, Amar L, Rault A, Henry JF, Carnaille B. Ectopic hormone-secreting pheochromocytoma: a francophone observational study. World J Surg. 2012;36(6):1382\u20138. https:\/\/doi.org\/10.1007\/s00268-012-1488-1.","journal-title":"World J Surg"},{"issue":"9","key":"1323_CR31","doi-asserted-by":"publisher","first-page":"e3374","DOI":"10.1210\/clinem\/dgaa423","volume":"105","author":"G Constantinescu","year":"2020","unstructured":"Constantinescu G, Langton K, Conrad C, Amar L, Assi\u00e9 G, Gimenez-Roqueplo AP, et al. Glucocorticoid excess in patients with pheochromocytoma compared with paraganglioma and other forms of hypertension. J Clin Endocrinol Metab. 2020;105(9):e3374\u201383. https:\/\/doi.org\/10.1210\/clinem\/dgaa423.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1323_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ecl.2011.02.002","volume":"40","author":"SM Zuber","year":"2011","unstructured":"Zuber SM, Kantorovich V, Pacak K. Hypertension in pheochromocytoma: characteristics and treatment. Endocrinol Metab Clin North Am. 2011;40(2):295\u2013311. https:\/\/doi.org\/10.1016\/j.ecl.2011.02.002.","journal-title":"Endocrinol Metab Clin North Am."},{"key":"1323_CR33","doi-asserted-by":"publisher","first-page":"3644212","DOI":"10.1155\/2022\/3644212","volume":"2022","author":"X Wang","year":"2022","unstructured":"Wang X, Zhao Q, Sang H, Dong J, Bai M. Research on the damage of adrenal pheochromocytoma to patients\u2019 cardiovascular vessels and its correlation with hypertension. J Oncol. 2022;2022:3644212. https:\/\/doi.org\/10.1155\/2022\/3644212.","journal-title":"J Oncol"},{"issue":"12","key":"1323_CR34","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S2213-8587(23)00256-5","volume":"11","author":"MA Nazari","year":"2023","unstructured":"Nazari MA, Hasan R, Haigney M, Maghsoudi A, Lenders JWM, Carey RM, Pacak K. Catecholamine-induced hypertensive crises: current insights and management. Lancet Diabetes Endocrinol. 2023;11(12):942\u201354. https:\/\/doi.org\/10.1016\/S2213-8587(23)00256-5. (Erratum in: Lancet Diabetes Endocrinol. 2024 Jan;12(1):e1. 10.1016\/S2213-8587(23)00362-5).","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1323_CR35","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","volume":"189","author":"M Fassnacht","year":"2023","unstructured":"Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023;189(1):G1\u201342. https:\/\/doi.org\/10.1093\/ejendo\/lvad066.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1323_CR36","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Endocrine society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915\u201342. https:\/\/doi.org\/10.1210\/jc.2014-1498. (Erratum in: J Clin Endocrinol Metab. 2023 Apr 13;108(5):e200. 10.1210\/clinem\/dgad064).","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"1323_CR37","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jama.2023.11305","volume":"330","author":"M Reincke","year":"2023","unstructured":"Reincke M, Fleseriu M. Cushing syndrome: A review. JAMA. 2023;330(2):170\u201381. https:\/\/doi.org\/10.1001\/jama.2023.11305.","journal-title":"JAMA"},{"issue":"12","key":"1323_CR38","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, et al. Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847\u201375. https:\/\/doi.org\/10.1016\/S2213-8587(21)00235-7.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1323_CR39","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1210\/jc.2010-1942","volume":"96","author":"RN Clayton","year":"2011","unstructured":"Clayton RN, Raskauskiene D, Reulen RC, et al. Mortality and morbidity in Cushing\u2019s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab. 2011;96:632\u201342.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1323_CR40","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1210\/jc.2018-02524","volume":"104","author":"O Ragnarsson","year":"2019","unstructured":"Ragnarsson O, Olsson DS, Papakokkinou E, Chantzichristos D, Dahlqvist P, Segerstedt E, et al. Overall and disease-specific mortality in patients with cushing disease: A swedish nationwide study. J Clin Endocrinol Metab. 2019;104(6):2375\u201384. https:\/\/doi.org\/10.1210\/jc.2018-02524.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1323_CR41","doi-asserted-by":"publisher","first-page":"R207","DOI":"10.1530\/EJE-20-1309","volume":"184","author":"EV Varlamov","year":"2021","unstructured":"Varlamov EV, Langlois F, Vila G, Fleseriu M. Management of endocrine disease: Cardiovascular risk assessment, thromboembolism, and infection prevention in Cushing\u2019s syndrome: a practical approach. Eur J Endocrinol. 2021;184(5):R207\u201324. https:\/\/doi.org\/10.1530\/EJE-20-1309.","journal-title":"Eur J Endocrinol"},{"key":"1323_CR42","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3389\/fendo.2019.00321","volume":"10","author":"M Barbot","year":"2019","unstructured":"Barbot M, Ceccato F, Scaroni C. The pathophysiology and treatment of hypertension in patients with cushing\u2019s syndrome. Front Endocrinol (Lausanne). 2019;10:321. https:\/\/doi.org\/10.3389\/fendo.2019.00321.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Suppl 1","key":"1323_CR43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000314315","volume":"92","author":"MV Cicala","year":"2010","unstructured":"Cicala MV, Mantero F. Hypertension in Cushing\u2019s syndrome: from pathogenesis to treatment. Neuroendocrinology. 2010;92(Suppl 1):44\u20139. https:\/\/doi.org\/10.1159\/000314315.","journal-title":"Neuroendocrinology"},{"issue":"4","key":"1323_CR44","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.ecl.2019.08.005","volume":"48","author":"LK Nieman","year":"2019","unstructured":"Nieman LK. Hypertension and cardiovascular mortality in patients with cushing syndrome. Endocrinol Metab Clin North Am. 2019;48(4):717\u201325. https:\/\/doi.org\/10.1016\/j.ecl.2019.08.005.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1323_CR45","doi-asserted-by":"crossref","unstructured":"Varlamov EV, Fernandes S, Fleseriu M. ACTH-dependent Cushing\u2019s syndrome. In: Pappachan JM, Fernandez CJ, editors. Endocrine Hypertension: From Basic Science to Clinical Practice. Eastbourne, UK: Elsevier; 2022. p. 183\u2013200.","DOI":"10.1016\/B978-0-323-96120-2.00011-X"},{"issue":"7","key":"1323_CR46","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","volume":"4","author":"R Pivonello","year":"2016","unstructured":"Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A. Complications of Cushing\u2019s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4(7):611\u201329. https:\/\/doi.org\/10.1016\/S2213-8587(16)00086-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1323_CR47","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/HJH.0000000000000415","volume":"33","author":"AM Isidori","year":"2015","unstructured":"Isidori AM, Graziadio C, Paragliola RM, Cozzolino A, Ambrogio AG, Colao A, Corsello SM, Pivonello R, ABC Study Group. The hypertension of Cushing\u2019s syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens. 2015;33(1):44\u201360. https:\/\/doi.org\/10.1097\/HJH.0000000000000415.","journal-title":"J Hypertens."},{"issue":"3","key":"1323_CR48","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1365-2265.2011.04206.x","volume":"76","author":"PM Toja","year":"2012","unstructured":"Toja PM, Branzi G, Ciambellotti F, Radaelli P, De Martin M, Lonati LM, Scacchi M, Parati G, Cavagnini F, Pecori GF. Clinical relevance of cardiac structure and function abnormalities in patients with Cushing\u2019s syndrome before and after cure. Clin Endocrinol (Oxf). 2012;76(3):332\u20138. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04206.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"1323_CR49","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s40618-020-01246-0","volume":"43","author":"A Lacroix","year":"2020","unstructured":"Lacroix A, Bronstein MD, Schopohl J, Delibasi T, Salvatori R, Li Y, et al. Long-acting pasireotide improves clinical signs and quality of life in Cushing\u2019s disease: results from a phase III study. J Endocrinol Invest. 2020;43(11):1613\u201322. https:\/\/doi.org\/10.1007\/s40618-020-01246-0.","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"1323_CR50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11102-016-0754-x","volume":"20","author":"A Lavrentaki","year":"2017","unstructured":"Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4\u20139. https:\/\/doi.org\/10.1007\/s11102-016-0754-x.","journal-title":"Pituitary"},{"issue":"2","key":"1323_CR51","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.mayocp.2021.11.007","volume":"97","author":"N Ershadinia","year":"2022","unstructured":"Ershadinia N, Tritos NA. Diagnosis and treatment of acromegaly: An update. Mayo Clin Proc. 2022;97(2):333\u201346. https:\/\/doi.org\/10.1016\/j.mayocp.2021.11.007.","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"1323_CR52","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022;10(11):804\u201326. https:\/\/doi.org\/10.1016\/S2213-8587(22)00244-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1323_CR53","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","volume":"40","author":"MR Gadelha","year":"2019","unstructured":"Gadelha MR, Kasuki L, Lim DST, Fleseriu M. Systemic complications of acromegaly and the impact of the current treatment landscape: An update. Endocr Rev. 2019;40(1):268\u2013332. https:\/\/doi.org\/10.1210\/er.2018-00115.","journal-title":"Endocr Rev"},{"issue":"4","key":"1323_CR54","doi-asserted-by":"publisher","first-page":"dgz06","DOI":"10.1210\/clinem\/dgz096","volume":"105","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: An update. J Clin Endocrinol Metab. 2020;105(4):dgz06. https:\/\/doi.org\/10.1210\/clinem\/dgz096.","journal-title":"J Clin Endocrinol Metab."},{"key":"1323_CR55","doi-asserted-by":"publisher","unstructured":"Vila G, Luger A, van der Lely AJ, Neggers SJCMM, Webb SM, Biller BMK, et al. Hypertension in acromegaly in relationship to biochemical control and mortality: Global ACROSTUDY outcomes. Front Endocrinol (Lausanne). 2020;11:577173. https:\/\/doi.org\/10.3389\/fendo.2020.577173.","DOI":"10.3389\/fendo.2020.577173"},{"key":"1323_CR56","doi-asserted-by":"crossref","unstructured":"Mihai G, Korbonits M. Hypertension in growth hormone excess and deficiency. In: Pappachan JM, Fernandez CJ, editors. Endocrine Hypertension: From Basic Science to Clinical Practice. Eastbourne, UK: Elsevier; 2022. p. 183\u2013200.","DOI":"10.1016\/B978-0-323-96120-2.00017-0"},{"issue":"1","key":"1323_CR57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, et al. Acromegaly consensus group. Consensus on criteria for acromegaly diagnosis and remission. Pituitary. 2024;27(1):7\u201322. https:\/\/doi.org\/10.1007\/s11102-023-01360-1. (Erratum in: Pituitary. 2024 Feb;27(1):88. 10.1007\/s11102-023-01373-w).","journal-title":"Pituitary."},{"issue":"8","key":"1323_CR58","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1210\/clinem\/dgad225","volume":"108","author":"AR Cappola","year":"2023","unstructured":"Cappola AR, Auchus RJ, El-Hajj Fuleihan G, Handelsman DJ, Kalyani RR, McClung M, Stuenkel CA, Thorner MO, Verbalis JG. Hormones and aging: An endocrine society scientific statement. J Clin Endocrinol Metab. 2023;108(8):1835\u201374. https:\/\/doi.org\/10.1210\/clinem\/dgad225.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1323_CR59","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1007\/s12020-022-02982-4","volume":"75","author":"SA Paschou","year":"2022","unstructured":"Paschou SA, Bletsa E, Stampouloglou PK, Tsigkou V, Valatsou A, Stefanaki K, Kazakou P, Spartalis M, Spartalis E, Oikonomou E, Siasos G. Thyroid disorders and cardiovascular manifestations: an update. Endocrine. 2022;75(3):672\u201383. https:\/\/doi.org\/10.1007\/s12020-022-02982-4.","journal-title":"Endocrine"},{"issue":"1","key":"1323_CR60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.amjms.2020.08.012","volume":"361","author":"AM Rivas","year":"2021","unstructured":"Rivas AM, Pena C, Kopel J, Dennis JA, Nugent K. Hypertension and hyperthyroidism: Association and pathogenesis. Am J Med Sci. 2021;361(1):3\u20137. https:\/\/doi.org\/10.1016\/j.amjms.2020.08.012.","journal-title":"Am J Med Sci"},{"issue":"6","key":"1323_CR61","doi-asserted-by":"publisher","first-page":"460","DOI":"10.2174\/1570161120666221004144414","volume":"20","author":"E Muzurovi\u0107","year":"2022","unstructured":"Muzurovi\u0107 E, Borozan S, Vujo\u0161evi\u0107 S, Gurnell M. Thyroid status and vascular risk: An update. Curr Vasc Pharmacol. 2022;20(6):460\u20132. https:\/\/doi.org\/10.2174\/1570161120666221004144414.","journal-title":"Curr Vasc Pharmacol"},{"issue":"25","key":"1323_CR62","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.2174\/1381612828666220620160516","volume":"28","author":"ZM Gluvic","year":"2022","unstructured":"Gluvic ZM, Zafirovic SS, Obradovic MM, Sudar-Milovanovic EM, Rizzo M, Isenovic ER. Hypothyroidism and risk of cardiovascular disease. Curr Pharm Des. 2022;28(25):2065\u201372. https:\/\/doi.org\/10.2174\/1381612828666220620160516.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"1323_CR63","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1161\/01.hyp.5.1.112","volume":"5","author":"I Saito","year":"1983","unstructured":"Saito I, Ito K, Saruta T. Hypothyroidism as a cause of hypertension. Hypertension. 1983;5(1):112\u20135. https:\/\/doi.org\/10.1161\/01.hyp.5.1.112.","journal-title":"Hypertension"},{"issue":"1","key":"1323_CR64","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1161\/01.hyp.11.1.78","volume":"11","author":"DH Streeten","year":"1988","unstructured":"Streeten DH, Anderson GH Jr, Howland T, Chiang R, Smulyan H. Effects of thyroid function on blood pressure. Recognition of hypothyroid hypertension. Hypertension. 1988;11(1):78\u201383. https:\/\/doi.org\/10.1161\/01.hyp.11.1.78.","journal-title":"Hypertension"},{"issue":"1","key":"1323_CR65","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1530\/EJE-13-0087","volume":"169","author":"BO Asvold","year":"2013","unstructured":"Asvold BO, Bj\u00f8ro T, Vatten LJ. Associations of TSH levels within the reference range with future blood pressure and lipid concentrations: 11-year follow-up of the HUNT study. Eur J Endocrinol. 2013;169(1):73\u201382. https:\/\/doi.org\/10.1530\/EJE-13-0087.","journal-title":"Eur J Endocrinol"},{"key":"1323_CR66","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3389\/fendo.2018.00454","volume":"9","author":"W He","year":"2018","unstructured":"He W, Li S, Zhang JA, Zhang J, Mu K, Li XM. Effect of levothyroxine on blood pressure in patients with subclinical hypothyroidism: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2018;9:454. https:\/\/doi.org\/10.3389\/fendo.2018.00454.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1323_CR67","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3389\/fendo.2019.00482","volume":"10","author":"E Berta","year":"2019","unstructured":"Berta E, Lengyel I, Halmi S, Zr\u00ednyi M, Erdei A, Harangi M, P\u00e1ll D, Nagy EV, Bodor M. Hypertension in thyroid disorders. Front Endocrinol (Lausanne). 2019;10:482. https:\/\/doi.org\/10.3389\/fendo.2019.00482.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"1323_CR68","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1507\/endocrj.EJ20-0796","volume":"68","author":"X Ding","year":"2021","unstructured":"Ding X, Zhao Y, Zhu CY, Wu LP, Wang Y, Peng ZY, Deji C, Zhao FY, Shi BY. The association between subclinical hypothyroidism and metabolic syndrome: an update meta-analysis of observational studies. Endocr J. 2021;68(9):1043\u201356. https:\/\/doi.org\/10.1507\/endocrj.EJ20-0796.","journal-title":"Endocr J"},{"issue":"1","key":"1323_CR69","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1365-2265.2005.02301.x","volume":"63","author":"P Iglesias","year":"2005","unstructured":"Iglesias P, Acosta M, S\u00e1nchez R, Fern\u00e1ndez-Reyes MJ, Mon C, D\u00edez JJ. Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function. Clin Endocrinol (Oxf). 2005;63(1):66\u201372. https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02301.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"1323_CR70","doi-asserted-by":"publisher","first-page":"R297","DOI":"10.1530\/EJE-17-0485","volume":"177","author":"J Pepe","year":"2017","unstructured":"Pepe J, Cipriani C, Sonato C, Raimo O, Biamonte F, Minisola S. Cardiovascular manifestations of primary hyperparathyroidism: A narrative review. Eur J Endocrinol. 2017;177(6):R297\u2013308. https:\/\/doi.org\/10.1530\/EJE-17-0485.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1323_CR71","doi-asserted-by":"publisher","first-page":"142","DOI":"10.21037\/gs.2019.10.21","volume":"9","author":"SB Fisher","year":"2020","unstructured":"Fisher SB, Perrier ND. Primary hyperparathyroidism and hypertension. Gland Surg. 2020;9(1):142\u20139. https:\/\/doi.org\/10.21037\/gs.2019.10.21.","journal-title":"Gland Surg."},{"key":"1323_CR72","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3389\/fendo.2020.00539","volume":"11","author":"MH Zheng","year":"2020","unstructured":"Zheng MH, Li FX, Xu F, Lin X, Wang Y, Xu QS, Guo B, Yuan LQ. The interplay between the renin-angiotensin-aldosterone system and parathyroid hormone. Front Endocrinol (Lausanne). 2020;11:539. https:\/\/doi.org\/10.3389\/fendo.2020.00539.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1323_CR73","first-page":"21","volume":"15","author":"C Letizia","year":"2001","unstructured":"Letizia C, Delfini E, Detoma G, Caliumi C, Minisola S, Diacinti D, et al. Renin-angiotensin-aldosterone and endothelin-1 systems in primary hyperparathyroidism associated with arterial hypertension. Ital J Miner Electrolyte Metab. 2001;15:21\u20136.","journal-title":"Ital J Miner Electrolyte Metab"},{"key":"1323_CR74","doi-asserted-by":"publisher","first-page":"1163877","DOI":"10.3389\/fendo.2023.1163877","volume":"14","author":"I Karwacka","year":"2023","unstructured":"Karwacka I, Kmie\u0107 P, Kaniuka-Jakubowska S, Pisowodzka I, Fija\u0142kowski M, Sworczak K. Improvement of hypertension control and left-ventricular function after cure of primary hyperparathyroidism. Front Endocrinol (Lausanne). 2023;14:1163877. https:\/\/doi.org\/10.3389\/fendo.2023.1163877.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1323_CR75","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s12020-016-1175-3","volume":"55","author":"M Karakose","year":"2017","unstructured":"Karakose M, Caliskan M, Arslan MS, Demirci T, Karakose S, Cakal E. The impact of parathyroidectomy on serum ADAMTS1, ADAMTS4 levels, insulin resistance, and subclinical cardiovascular disease in primary hyperparathyroidism. Endocrine. 2017;55(1):283\u20138. https:\/\/doi.org\/10.1007\/s12020-016-1175-3.","journal-title":"Endocrine"},{"issue":"1","key":"1323_CR76","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamasurg.2019.3950","volume":"155","author":"AN Graff-Baker","year":"2020","unstructured":"Graff-Baker AN, Bridges LT, Chen Q, Faries MB, Said M. Parathyroidectomy for patients with primary hyperparathyroidism and associations with hypertension. JAMA Surg. 2020;155(1):32\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2019.3950.","journal-title":"JAMA Surg"},{"issue":"11","key":"1323_CR77","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/jbmr.4677","volume":"37","author":"JP Bilezikian","year":"2020","unstructured":"Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE, Marcocci C, Minisola S, Perrier N, Sitges-Serra A, Thakker RV, Guyatt G, Mannstadt M. Evaluation and management of primary hyperparathyroidism: Summary statement and guidelines from the fifth international workshop. J Bone Miner Res. 2020;37(11):2293\u2013314. https:\/\/doi.org\/10.1002\/jbmr.4677.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1323_CR78","doi-asserted-by":"publisher","first-page":"CD03035","DOI":"10.1002\/14651858.CD013035.pub2","volume":"3","author":"JM Pappachan","year":"2023","unstructured":"Pappachan JM, Lahart IM, Viswanath AK, Borumandi F, Sodi R, Metzendorf MI, Bongaerts B. Parathyroidectomy for adults with primary hyperparathyroidism. Cochrane Database Syst Rev. 2023;3(3):CD03035. https:\/\/doi.org\/10.1002\/14651858.CD013035.pub2.","journal-title":"Cochrane Database Syst Rev."},{"issue":"4","key":"1323_CR79","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ecl.2019.08.007","volume":"48","author":"SM Herrmann","year":"2019","unstructured":"Herrmann SM, Textor SC. Renovascular hypertension. Endocrinol Metab Clin North Am. 2019;48(4):765\u201378. https:\/\/doi.org\/10.1016\/j.ecl.2019.08.007.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"9","key":"1323_CR80","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"V Aboyans","year":"2018","unstructured":"Aboyans V, Ricco JB, Bartelink ML, Bj\u00f6rck M, Brodmann M, Cohnert T, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J. 2018;39(9):763\u2013816. https:\/\/doi.org\/10.1093\/eurheartj\/ehx095.","journal-title":"Eur Heart J"},{"issue":"3","key":"1323_CR81","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3390\/life11030208","volume":"11","author":"L Dobrek","year":"2021","unstructured":"Dobrek L. An outline of renal artery stenosis pathophysiology-A narrative review. Life (Basel). 2021;11(3):208. https:\/\/doi.org\/10.3390\/life11030208.","journal-title":"Life (Basel)"},{"issue":"3","key":"1323_CR82","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/cphy.c130040","volume":"4","author":"MA Sparks","year":"2014","unstructured":"Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical renin-angiotensin system in kidney physiology. Compr Physiol. 2014;4(3):1201\u201328. https:\/\/doi.org\/10.1002\/cphy.c130040.","journal-title":"Compr Physiol"},{"issue":"11","key":"1323_CR83","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1001\/jamainternmed.2014.4332","volume":"174","author":"AA Bavry","year":"2014","unstructured":"Bavry AA, Kapadia SR, Bhatt DL, Kumbhani DJ. Renal artery revascularization: Updated meta-analysis with the CORAL trial. JAMA Intern Med. 2014;174(11):1849\u201351. https:\/\/doi.org\/10.1001\/jamainternmed.2014.4332.","journal-title":"JAMA Intern Med"},{"key":"1323_CR84","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0140-6736(13)60734-5","volume":"383","author":"AS Jordan","year":"2014","unstructured":"Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. Lancet. 2014;383:736\u201347.","journal-title":"Lancet"},{"issue":"4","key":"1323_CR85","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/diseases9040088","volume":"9","author":"AK Mitra","year":"2021","unstructured":"Mitra AK, Bhuiyan AR, Jones EA. Association and risk factors for obstructive sleep apnea and cardiovascular diseases: A systematic review. Diseases. 2021;9(4):88. https:\/\/doi.org\/10.3390\/diseases9040088.","journal-title":"Diseases"},{"issue":"1","key":"1323_CR86","doi-asserted-by":"publisher","first-page":"e010440","DOI":"10.1161\/JAHA.118.010440","volume":"8","author":"JR Tietjens","year":"2019","unstructured":"Tietjens JR, Claman D, Kezirian EJ, De Marco T, Mirzayan A, Sadroonri B, et al. Obstructive sleep apnea in cardiovascular disease: A review of the literature and proposed multidisciplinary clinical management strategy. J Am Heart Assoc. 2019;8(1):e010440. https:\/\/doi.org\/10.1161\/JAHA.118.010440.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"1323_CR87","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11906-022-01181-w","volume":"24","author":"J Brown","year":"2022","unstructured":"Brown J, Yazdi F, Jodari-Karimi M, Owen JG, Reisin E. Obstructive sleep apnea and hypertension: Updates to a critical relationship. Curr Hypertens Rep. 2022;24(6):173\u201384. https:\/\/doi.org\/10.1007\/s11906-022-01181-w.","journal-title":"Curr Hypertens Rep"},{"issue":"2","key":"1323_CR88","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1378\/chest.06-1442","volume":"131","author":"MN Pratt-Ubunama","year":"2007","unstructured":"Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007;131(2):453\u20139. https:\/\/doi.org\/10.1378\/chest.06-1442.","journal-title":"Chest"},{"key":"1323_CR89","doi-asserted-by":"publisher","first-page":"976979","DOI":"10.3389\/fendo.2022.976979","volume":"13","author":"HH Loh","year":"2022","unstructured":"Loh HH, Sukor N. Primary aldosteronism and obstructive sleep apnea: What do we know thus far? Front Endocrinol (Lausanne). 2022;13:976979. https:\/\/doi.org\/10.3389\/fendo.2022.976979.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"1323_CR90","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1378\/chest.07-1170","volume":"132","author":"SC Gon\u00e7alves","year":"2007","unstructured":"Gon\u00e7alves SC, Martinez D, Gus M, de Abreu-Silva EO, Bertoluci C, Dutra I, Branchi T, Moreira LB, Fuchs SC, de Oliveira AC, Fuchs FD. Obstructive sleep apnea and resistant hypertension: a case-control study. Chest. 2007;132(6):1858\u201362. https:\/\/doi.org\/10.1378\/chest.07-1170.","journal-title":"Chest"},{"key":"1323_CR91","doi-asserted-by":"crossref","unstructured":"Oduro-Donkor D, Barber TM. Obesity, insulin resistance and obstructive sleep apnea. In: Pappachan JM, Fernandez CJ, editors. Endocrine Hypertension: From Basic Science to Clinical Practice. Eastbourne, UK: Elsevier; 2022. p. 263\u2013275.","DOI":"10.1016\/B978-0-323-96120-2.00012-1"},{"key":"1323_CR92","doi-asserted-by":"crossref","unstructured":"Gurpinar B, Guran T. Congenital adrenal hyperplasia and hypertension. In: Pappachan JM, Fernandez CJ, editors. Endocrine Hypertension: From Basic Science to Clinical Practice. Eastbourne, UK: Elsevier; 2022. p. 113\u2013125.","DOI":"10.1016\/B978-0-323-96120-2.00015-7"},{"key":"1323_CR93","doi-asserted-by":"crossref","unstructured":"Assadi F, Hooman N, Mazaheri M, Sharbaf FG. Endocrine hypertension: discovering the inherited causes. In: Pappachan JM, Fernandez CJ, editors. Endocrine Hypertension: From Basic Science to Clinical Practice. Eastbourne, UK: Elsevier; 2022. p. 127\u2013148.","DOI":"10.1016\/B978-0-323-96120-2.00001-7"},{"key":"1323_CR94","unstructured":"Valaiyapathi B, Ashraf AP. Endocrine hypertension in children. In: Pappachan JM, Fernandez CJ, editors. Endocrine Hypertension: From Basic Science to Clinical Practice. Eastbourne, UK: Elsevier; 2022. p. 183\u2013200."}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-025-01323-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-025-01323-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-025-01323-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:03:16Z","timestamp":1770476596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-025-01323-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1323"],"URL":"https:\/\/doi.org\/10.1007\/s11906-025-01323-w","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"2 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"8"}}